Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma

Cancer

Volumn 119, Issue 17, 2013, Pages 3148-3155

  Colbert, Lauren E ^a   Fisher, Sarah B ^a   Hardy, Claire W ^a   Hall, William A ^a   Saka, Burcu ^a   Shelton, Joseph W ^a   Petrova, Aleksandra V ^a   Warren, Matthew D ^a   Pantazides, Brooke G ^a   Gandhi, Khanjan ^b   Kowalski, Jeanne ^b   Kooby, David A ^a,c   El Rayes, Bassel F ^a   Staley III, Charles A ^a   Adsay, N Volkan ^a   Curran, Walter J ^a   Landry, Jerome C ^a   Maithel, Shishir K ^a   Yu, David S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

biomarker; mixed lineage kinase domain like protein (MLKL); necroptosis; necrosis; pancreatic cancer

Indexed keywords

GEMCITABINE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CELL DEATH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SCORING SYSTEM;

EID: 84882635576     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28144     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297: 267-277.
3. Heinemann V, Haas M, Boeck S,. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev. 2012; 38: 843-853.
4. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995; 221: 721-731; discussion 731-733.
5. Vanlangenakker N, Vanden Berghe T, Vandenabeele P,. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ. 2012; 19: 75-86.
6. Tenev T, Bianchi K, Darding M, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011; 43: 432-448.
7. Coupienne I, Fettweis G, Piette J,. RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT. Lasers Surg Med. 2011; 43: 557-564.
8. Vandenabeele P, Declercq W, Van Herreweghe F, Vanden Berghe T,. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal. 2010; 3: re4.
9. Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012; 148: 213-227.
10. Zhou Z, Han V, Han J,. New components of the necroptotic pathway. Protein Cell. 2012; 3: 811-817.
11. Paulsen RD, Soni DV, Wollman R, et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol Cell. 2009; 35: 228-239.
12. Cotta-Ramusino C, McDonald ER 3rd, Hurov K, Sowa ME, Harper JW, Elledge SJ,. A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science. 2011; 332: 1313-1317.
13. Maupin KA, Sinha A, Eugster E, et al. Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems. PLoS One. 2010; 5: e13002.
14. Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009; 16: 259-266.
15. Maithel SK, Coban I, Kneuertz PJ, et al. Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. Ann Surg Oncol. 2011; 18: 2699-2705.
16. Fisher SB, Patel SH, Bagci P, et al. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. Cancer. 2013; 119: 445-453.
17. Basturk O, Singh R, Kaygusuz E, et al. GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas. 2011; 40: 187-192.
18. Liu X, Lai L, Wang X, et al. Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. Cancer Res. 2011; 71: 3202-3213.
19. Jamieson NB, Carter CR, McKay CJ, Oien KA,. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res. 2011; 17: 3316-3331.
20. Ansari D, Rosendahl A, Elebro J, Andersson R,. Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. Br J Surg. 2011; 98: 1041-1055.
21. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009; 136: 187-195.
22. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE,. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 2004; 23: 1539-1548.
23. Metzger R, Bollschweiler E, Holscher AH, Warnecke-Eberz U,. ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol. 2010; 6: 1735-1749.
24. Denlinger CS, Cohen SJ,. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Curr Treat Options Oncol. 2007; 8: 339-351.
25. Xu X, Wang Y, Chen J, et al. High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2012; 16: 1493-1498.
26. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009; 27: 1806-1813.
27. Bachet JB, Marechal R, Demetter P, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol. 2012; 23: 2327-2335.
28. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA,. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene. 2004; 23: 8571-8580.